Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-LEAD: Pemafibrate after lower extremity EVT with DCB in hypertriglyceridemia and LEAD
jRCTs051240272Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate in arteriosclerosis obliterans (2 arms), sponsored by Kowa Company, Ltd. Started Apr 2025; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCTs051240272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240272.